Clinical Trials

Key inclusion criteria: -Histologically confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable for primary resection by treating surgeon, except for N2 and T4 tumors. -Subject must be eligible for surgery and with a planned surgical resection in approximately 4-6 weeks (after the first dose of study treatment). -A mandatory newly obtained tissue biopsy is required for study enrollment. An archival biopsy is also acceptable if obtained up to 6 months before first day of study treatment and if the subject did not go through antineoplastic systemic therapies between biopsy collection date and beginning of study treatment. -Eastern Cooperative oncology group (ECOG) performance status of 0 or 1. Key exclusion criteria: -Subjects with unresectable or metastatic disease. -History of severe hypersensitivity reactions to monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction -Subjects who received prior systemic therapy (including chemotherapy, other anti-cancer therapies and any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) in the past 3 years before screening -Active, known or suspected autoimmune disease or documented history of autoimmune disease. -Subject with suspected or proven immunocompromised state or infections Other protocol-defined inclusion/exclusion criteria may apply.